South Jersey health care system offers treatment to keep COVID-19 patients out of the hospital
A health care system in South Jersey is hoping to keep hospital beds open by providing a treatment for COVID-19 patients that will help keep them home.
News 12 Staff
•
Jan 7, 2021, 1:24 PM
•
Updated 1,197 days ago
Share:
More Stories
Hometown Heroes in New Jersey
2ds ago
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
199ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
211ds ago
Murphy administration: No plans to implement any COVID-19 restrictions
217ds ago0:39
Cape May hospital asking patients to wear mask amid COVID surge
218ds ago2:57
Lawmakers call for investigation, overhaul following DOJ report about NJ’s COVID response in veterans homes
220ds agoHometown Heroes in New Jersey
2ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
199ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
211ds agoMurphy administration: No plans to implement any COVID-19 restrictions
217ds ago0:39
Cape May hospital asking patients to wear mask amid COVID surge
218ds ago2:57
Lawmakers call for investigation, overhaul following DOJ report about NJ’s COVID response in veterans homes
220ds agoA health care system in South Jersey is hoping to keep hospital beds open by providing a treatment for COVID-19 patients that will help keep them home.
Cherry Hil resident Jay Siegmeister is a COVID-19 survivor thanks to a new outpatient therapy at Virtua Health. The treatment known as Bamlan/Vimab is a monoclonal antibody treatment administered through an infusion.
“Normally the bodies form its own antibodies but sometimes that’s delayed when fighting off COVID-19 and we really need that early push on the antibodies,” says Dr. Martin Topiel, chief of Infectious Diseases at Virtua Health. “This monoclonal antibody provides that and hopefully stops the symptoms very early.”
Siegmeister says he felt better the next day and made a full recovery within a week.
The FDA approved the treatment in early December. Since then, Virtua officials say they’ve treated about 145 patients.
To qualify for the treatment, a patient must have mild or moderate symptoms and a qualifying risk factor such as diabetes, obesity or an immunosuppressive disease.
